Immunotherapies and targeted therapies—implying inhibition of human epidermal growth factor receptor 2 (HER2) signaling with either antibodies (trastuzumab, pertuzumab) or TKIs (lapatinib)—have ameliorated survival of patients with HER2-positive breast cancer [2,13]. The gene discussed is ERBB2; the disease is breast carcinoma.